Gene delivery of AGAT and GAMT boosts creatine levels in creatine transporter deficiency patient fibroblasts
PLOS One · 2025
DOI: 10.1371/journal.pone.0319350 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Chloe Wells und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Utah, Salt Lake City, Utah, United States of America. Hauptthemen laut MEDLINE: Creatine, Fibroblasts, Plasma Membrane Neurotransmitter Transport Proteins, Guanidinoacetate N-Methyltransferase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Howard Hughes Medical Institute.
Abstract (Originalsprache)
Creatine is a critical metabolite used to buffer cellular energy demands in highly energetic tissues such as the brain and muscle. Genetic defects in endogenous creatine synthesis or transport across cellular membranes lead to a common set of phenotypes referred to as Cerebral Creatine Deficiency Syndrome (CCDS). The most common form of CCDS is Creatine Transporter 1 (CT1) Deficiency (CTD). It accounts for ~ 70% of cases and results from loss-of-function mutations in the X-linked gene SLC6A8 . Affected individuals suffer from intellectual disability, autistic-like behaviors, and epilepsy. There are currently no effective therapies for this disorder, but gene therapy has emerged as a potential approach. The two enzymes which comprise the endogenous creatine synthetic pathway (AGAT and GAMT) are selectively expressed by specific cell types throughout the body. However, after synthesized, creatine uptake relies on the protein product of SLC6A8 , CT1, to transport creatine into target cell types. We hypothesized that gene delivery of GATM (encoding AGAT) and GAMT into end-user cell types would bypass the need for CT1, allowing for intracellular synthesis of creatine. We tested this strategy in two human cell types: HEK293T cells and primary fibroblasts. Co-delivery of GATM and GAMT increased internal creatine concentrations by 7.6-fold in HEK293T cells and 12.3-fold in healthy control fibroblasts. We then employed this approach to primary fibroblasts from patients with CTD. This resulted in an up to 11.6-fold increase in intracellular creatine concentrations, far exceeding the intracellular concentration of creatine in healthy control fibroblasts. Importantly, overexpression of AGAT and GAMT resulted in proper targeting of these enzymes to their natural cellular compartment and did not impair the growth of patient fibroblasts. These findings establish gene therapy with GATM and GAMT as a potential strategy for patients with CTD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Utah, Salt Lake City, Utah, United States of America.
- Department of Biochemistry, University of Utah, Salt Lake City, Utah, United States of America.
- Howard Hughes Medical Institute, Salt Lake City, Utah, United States of America.
- Diabetes & Metabolism Research Center, University of Utah, Salt Lake City, Utah, United States of America.
ORCID-Profile: Jon Sorgenfrei, Devin Albertson, Steven Andrew Baker
Förderung
- Howard Hughes Medical Institute
Zitieren
APA
Wells, C., Sorgenfrei, J., Johnson, S. L., Albertson, D., Rutter, J., & Baker, S. A. (2025). Gene delivery of AGAT and GAMT boosts creatine levels in creatine transporter deficiency patient fibroblasts. PLOS One. https://doi.org/10.1371/journal.pone.0319350
Vancouver
Wells C, Sorgenfrei J, Johnson SL, Albertson D, Rutter J, Baker SA. Gene delivery of AGAT and GAMT boosts creatine levels in creatine transporter deficiency patient fibroblasts. PLOS One. 2025. doi:10.1371/journal.pone.0319350
BibTeX
@article{Wells2025,
author = {Wells, Chloe and Sorgenfrei, Jon and Johnson, Sadie L and Albertson, Devin and Rutter, Jared and Baker, Steven Andrew},
title = {Gene delivery of AGAT and GAMT boosts creatine levels in creatine transporter deficiency patient fibroblasts},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0319350}
}
EUVIMED